(Firastotug)Biosimilar Reference Antibody-GS40269 新品

货号：GS40269

Firastotug is an investigational immunoglobulin G1 kappa (IgG1κ) monoclonal antibody being developed for cancer immunotherapy. It functions as a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor. By binding to CTLA-4 with high affinity, firastotug blocks its interaction with its ligands, B7-1 (CD80) and B7-2 (CD86), on antigen-presenting cells. This blockade prevents CTLA-4 from delivering an inhibitory signal to T cells, thereby releasing a key early "brake" on T-cell activation. As an IgG1κ antibody, firastotug may also engage immune effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), potentially depleting regulatory T cells (Tregs) that express high levels of CTLA-4 within the tumor microenvironment, further enhancing anti-tumor immunity.